Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

Blood

Volumn 106, Issue 10, 2005, Pages 3609-3617

  Stühmer, Thorsten ^a   Chatterjee, Manik ^a   Hildebrandt, Martin ^a   Herrmann, Pia ^a   Gollasch, Hella ^a   Gerecke, Christian ^a   Theurich, Sebastian ^a   Cigliano, Luisa ^a   Manz, Rudolf A ^a   Daniel, Peter T ^a   Bommert, Kurt ^a   Vassilev, Lyubomir T ^a   Bargou, Ralf C ^a  

^a Department of Internal Medicine II ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; SMALL MOLECULE ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STROMA CELL; TOXICITY TESTING;

EID: 27744487598     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1489     Document Type: Article

References (32)

1. Barillé-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Program). 2003;248-278.
2. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618.
3. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.
4. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet. 2000;355:248-250.
5. Chatterjee M, Stühmer T, Herrmann P, Bommert K, Dörken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 2004;104:3712-3721.
6. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000;12:557-563.
7. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
8. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003;10:431-442.
9. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-126.
10. Momand J, Wu H-H, Dasgupta G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene. 2000;242:15-29.
11. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137.
12. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer. 2004;91:1415-1419.
13. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003;3:103-109.
14. Portier M, Molès J-P, Mazars G-R, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7:2539-2543.
15. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802-809.
16. Avet-Loiseau H, Li J-Y, Godon C, et al. p53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999;106:717-719.
17. Schultheis B, Kramer A, Willer A, Hegenbart U, Goldschmidt H, Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia. 1999;13:2099-2103.
18. Elnenaei MO, Gruszka-Westwood AM, A'Hern R, et al. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica. 2003;88:529-537.
19. Chang H, Qi C, Yi Q-L, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105:358-360.
20. Mazars G-R, Portier M, Zhang X-G, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene. 1992;7:1015-1018.
21. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81:128-135.
22. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-848.
23. + cells: factors influencing component purity and yield. Transfusion. 2000;40:507-512.
24. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99:3398-3403.
25. Chatterjee M, Hönemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood. 2002;100:3311-3318.
26. Sturm I, Köhne C-H, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999;17:1364-1374.
27. Mrózek A, Petrowsky H, Sturm I, et al. Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ. 2003;10:461-467.
28. International Agency for Research on Cancer. IARC TP53 Mutation Database. http://www-p53.iarc.fr/index.html. Accessed June 2, 2005.
29. Drach J, Ackermann J, Kaufmann H, Königsberg R, Huber H. Deletions of the p53 gene in multiple myeloma. Br J Haematol. 2000;108:886.
30. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol. 2003;23:462-473.
31. Teoh G, Urashima M, Ogata A, et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 1997;90:1982-1992.
32. Quesnel B, Preudhomme C, Oscier D, et al. Overexpression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol. 1994;88:415-418.